In this excerpt, Mitch Herndon, Patient Engagement Lead for UCB’s Global Clinical Sciences & Operations, talks about the importance of incorporating the patient perspective into clinical research studies. Read the full article on LinkedIn. 

Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients

UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

It is estimated that a fragility fracture occurs every 3 seconds— totaling nearly 9 million fractures annually, worldwide. Oftentimes people think fragile bones are an inevitable part of getting older. But a broken hip or bone may more commonly be the result of an underlying condition: osteoporosis. So common that by the time you finish reading the title of this post, a fragility fracture due to osteoporosis has occurred.

• Oral presentation of results from C-AXSPAND, the first Phase 3 study to follow non-radiographic axial spondyloarthritis (nr-axSpA) patients for 52 weeks, demonstrated positive results for CIMZIA^®(certolizumab pegol) in this patient population when added to common background medications

On World Osteoporosis Day, Survey Finds the Impact of Fractures Due to Osteoporosis is Being Ignored

UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis into Confirmatory Development Phase

As part of World Arthritis Day, we’re shining a spotlight on rheumatoid arthritis (RA). Learn more about RA, which is just one of the many different types of arthritis that affect the people we’re honoring today.

Today, we’re taking a deeper dive into some of the benefits and potential disadvantages of participating in a clinical research study. These points should be used in conjunction with advice from a healthcare professional when considering if participation in a clinical research study is right for you. 

Today, our Research Triangle Park office in Raleigh, North Carolina hosted its fifth annual Academic Engagement Night.